Shop

A 16-amino-acid mitochondrial-derived peptide studied in research into metabolic homeostasis and AMPK-pathway signalling in experimental models.

A synthetic tetrapeptide studied in research into telomerase activity and cellular-senescence pathways in experimental models.

A synthetic heptapeptide derived from ACTH (4–10), studied in research into BDNF expression and neuropeptide-signalling pathways in experimental models.

A synthetic melanocortin-receptor agonist studied in research into MC4R signalling pathways in experimental models.

A synthetic cyclic analogue of α-melanocyte-stimulating hormone (α-MSH) studied in research into melanocortin-receptor signalling pathways in experimental models.

A mitochondria-targeting tetrapeptide studied in research into cardiolipin interactions and mitochondrial-function pathways in experimental models.

A synthetic 28-amino-acid N-terminally acetylated peptide studied in research into Toll-like-receptor signalling and dendritic-cell activation in experimental models.

A synthetic growth-hormone-releasing hormone (GHRH) analogue studied in research into GHRH-receptor signalling, the GH axis and metabolic pathways in experimental models.

A synthetic peptide fragment of the C-terminal region (residues 176–191) of human growth hormone, studied in research for lipolytic and metabolic-pathway activity in experimental models.

A synthetic analogue of the first 29 amino acids of growth-hormone-releasing hormone (GHRH 1–29), studied in research into GHRH-receptor signalling and the GH axis in experimental models.

A synthetic lipidated peptide studied as a triple agonist of the GLP-1, GIP and glucagon receptors in experimental models.

A synthetic growth-hormone-releasing hexapeptide studied in research into ghrelin and GHS-receptor signalling within GH-axis models.

A coenzyme studied in research into cellular-energy metabolism and sirtuin-pathway signalling in experimental models. Not a peptide.

A GH-axis research bundle: one vial of CJC-1295 (No DAC, 5 mg) and one vial of Ipamorelin (5 mg). The compounds are not pre-mixed.

A synthetic pentadecapeptide derived from a gastric-juice protein fragment, studied in experimental models of tissue-protection and angiogenesis pathways.

10 mg lyophilised BPC-157 for laboratories that prefer a larger working aliquot of this pentadecapeptide reference material.

A synthetic fragment of thymosin beta-4 studied in research into actin-binding, cell-migration and tissue-repair pathways in experimental models.

2 mg lyophilised TB-500 (thymosin beta-4 fragment) for smaller-scale laboratory work.

The copper(II) complex of the tripeptide GHK, studied in research into extracellular-matrix signalling and skin-model biochemistry.

100 mg GHK-Cu copper tripeptide for laboratories needing a larger lyophilised stock of this reference complex.

The C-terminal tripeptide of α-MSH (Lys-Pro-Val), studied in experimental models of melanocortin and inflammatory-signalling pathways.

10 mg lyophilised KPV tripeptide reference material.

A 37-residue human cathelicidin peptide studied in research into host-defence and membrane-interaction models.

A selective pentapeptide growth-hormone secretagogue-receptor agonist studied in GH-axis signalling models.

2 mg lyophilised ipamorelin for smaller GH-axis laboratory protocols.

A 29-residue GHRH analogue (modified GRF 1-29) without Drug Affinity Complex, studied in GH-axis receptor models.

2 mg lyophilised CJC-1295 No DAC (modified GRF 1-29).

CJC-1295 with Drug Affinity Complex, a GHRH analogue studied in extended GH-axis signalling research.

A synthetic hexapeptide growth-hormone secretagogue studied at the ghrelin/GHS receptor in experimental models.

A hexapeptide GHS-receptor ligand studied in growth-hormone secretagogue research models.

2 mg lyophilised hexarelin reference peptide.

A recombinant analogue of insulin-like growth factor 1 with an N-terminal extension and Arg3 substitution, supplied as a research protein.

A pegylated analogue of mechano growth factor (IGF-1 Ec) studied in muscle-repair signalling models.

Mechano growth factor, a splice variant of IGF-1 studied in mechanical-load and repair pathway research.

A synthetic analogue of tuftsin studied in research into GABAergic and anxiolytic-pathway models.

A nonapeptide originally isolated from cerebral venous blood, studied in sleep-regulation and neuromodulation models.

An angiotensin IV-related oligopeptide studied in hepatocyte-growth-factor/c-Met signalling models.

A neurotrophic peptide derivative studied in experimental models of neuronal signalling and CNTF-pathway research.

A Semax analogue bearing an N-terminal adamantane modification, studied in neuropeptide-signalling research.

The C-terminal decapeptide of kisspeptin, studied as a GPR54/KISS1R ligand in reproductive-axis research models.

A long-acting amylin-analogue peptide studied in metabolic and satiety-pathway receptor models. Research chemical only.

A lipidated GLP-1 receptor agonist peptide supplied strictly as a lyophilised laboratory reference compound — not a licensed medicine.

A dual GIP and GLP-1 receptor agonist peptide for laboratory receptor-binding and pathway work. Not a licensed medicine.

10 mg lyophilised retatrutide (triple GLP-1/GIP/glucagon agonist analogue) for laboratory research. Not a medicine.

5 mg lyophilised retatrutide reference peptide for smaller metabolic-pathway assays.

20 mg lyophilised retatrutide for metabolic-pathway laboratory work. Research chemical — not a licensed medicine.

15 mg lyophilised retatrutide (triple GLP-1/GIP/glucagon agonist analogue) for laboratory research. Not a medicine.

50 mg lyophilised retatrutide for laboratories that want a larger working aliquot. HPLC ≥99%. Research use only — not a pre-filled pen.

40 mg lyophilised retatrutide (same CAS as the 5 / 10 / 30 mg vials). Not a pre-filled pen and not a medicine.

60 mg lyophilised retatrutide for laboratories that want a larger working aliquot. HPLC ≥99%. Research use only.

500 mg NAD+ coenzyme (not a peptide) for cellular-energy and sirtuin-pathway laboratory work.

A D-retro-inverso peptide designed to interfere with FOXO4–p53 interaction, studied in cellular-senescence research models.

A thymic peptide preparation analogue studied in immune-regulation research models.

An octapeptide analogue of SNAP-25 studied in cosmetic-science and SNARE-complex in-vitro models.

Palmitoyl pentapeptide-4 studied in extracellular-matrix and cosmetic-science laboratory models.

N-palmitoyl GHK tripeptide studied in matrix-signalling and cosmetic-science assays.

An 11-residue peptide derived from erythropoietin, studied at the innate repair receptor in experimental models.

The cyclic nonapeptide hormone oxytocin, supplied as a lyophilised laboratory reference — not a licensed medicine.

A 344-residue follistatin isoform studied as an activin/myostatin-binding protein in laboratory models.

A synthetic GnRH analogue decapeptide for receptor-binding research. Not a licensed medicine.

A synthetic tripeptide bioregulator (Glu-Asp-Arg) studied in pineal and neuronal-model research.

A synthetic tripeptide bioregulator studied in cartilage and connective-tissue research models.

A dipeptide bioregulator (Lys-Glu) studied in immune-regulation laboratory models.

A synthetic tripeptide bioregulator studied in vascular-endothelium research models.

N-terminally acetylated AEDG tetrapeptide, an analogue of epithalon for senescence-pathway laboratory work.

A small-molecule NNMT-pathway research compound supplied as a lyophilised solid for metabolic laboratory models. Not a peptide, listed alongside the research catalogue for convenience.

An α-MSH analogue for melanocortin-receptor laboratory work. Not supplied for tanning or any human use.

An ERR-pathway research ligand for metabolic laboratory models. Defined chemical supply — not a medicine.

A decapeptide gonadotropin-releasing hormone analogue for receptor and assay research. Not a fertility medicine.

BPC-157 5 mg and TB-500 5 mg as two separate lyophilised vials. Not pre-mixed. Each vial is independently HPLC-tested.

BPC-157 10 mg and TB-500 10 mg as two separate lyophilised vials. The 10+10 split UK catalogues list as a 20 mg Wolverine set. Not pre-mixed. Each vial is independently HPLC-tested.

GHK-Cu, BPC-157 and TB-500 as three separate lyophilised vials. Not pre-mixed.

70 mg GLOW set: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg as three separate vials. Not pre-mixed. Same 10% under typical UK list as the rest of the catalogue.

80 mg KLOW set: GHK-Cu 50 mg, TB-500 10 mg, BPC-157 10 mg, KPV 10 mg as four separate vials. Not a single mixed powder unless stated on the vial.

2 mg BPC-157 for smaller research aliquots.

10 mg TB-500 (thymosin β4 fragment) research vial.

10 mg GHK-Cu copper tripeptide research vial.

2 mg KPV research vial.

10 mg LL-37 research vial.

10 mg Ipamorelin research vial.

10 mg CJC-1295 (No DAC) research vial.

2 mg CJC-1295 with DAC research vial.

10 mg CJC-1295 with DAC research vial.

5 mg GHRP-2 research vial.

5 mg Hexarelin research vial.

0.1 mg IGF-1 LR3 research vial.

5 mg PEG-MGF research vial.

5 mg MGF research vial.

2 mg Semaglutide research vial.

10 mg Semaglutide research vial.

5 mg Tirzepatide research vial.

15 mg Tirzepatide research vial.

30 mg Tirzepatide research vial.

10 mg Cagrilintide research vial.

5 mg MOTS-c research vial.

40 mg MOTS-c research vial.

2 mg AOD-9604 research vial.

5 mg Epithalon research vial.

50 mg Epithalon research vial.

250 mg NAD+ research vial.

5 mg FOXO4-DRI research vial.

10 mg Semax research vial.

30 mg Semax research vial.

10 mg Selank research vial.

2 mg DSIP research vial.

10 mg P21 research vial.

10 mg Adamax research vial.

5 mg Dihexa research vial.

5 mg PT-141 research vial.

5 mg Melanotan 2 research vial.

5 mg Melanotan 1 research vial.

5 mg SS-31 (Elamipretide) research vial.

10 mg Thymosin Alpha-1 research vial.

2 mg Tesamorelin research vial.

5 mg Tesamorelin research vial.

2 mg Sermorelin research vial.

10 mg Sermorelin research vial.

5 mg GHRP-6 research vial.

10 mg Kisspeptin-10 research vial.

0.2 mg Follistatin 344 research vial.

5 mg Triptorelin research vial.

5 mg Gonadorelin research vial.

10 mg Thymalin research vial.

2 mg Oxytocin research vial.

10 mg Pinealon (EDR) research vial. Separate SKU from the 20 mg listing.

10 mg Cartalax research vial.

10 mg Vilon research vial.

20 mg Vesugen research vial.

10 mg Epitalon (sodium) research vial.

5 mg SNAP-8 research vial.

5 mg Matrixyl research vial.

5 mg ARA-290 research vial.

10 mg SLU-PP-332 research vial.

10 mg 5-Amino-1MQ research vial.

15 mg BPC-157 research vial — the extra size UK catalogues list above 10 mg.

15 mg TB-500 (thymosin β4 fragment) research vial.

5 mg GHK-Cu copper tripeptide research vial.

20 mg GHK-Cu copper tripeptide research vial.

30 mg GHK-Cu copper tripeptide research vial.

20 mg Tirzepatide research vial.

8 mg Semaglutide research vial.

1 mg Semaglutide research vial for small-aliquot assays.

20 mg MOTS-c research vial.

10 mg AOD-9604 research vial.

100 mg NAD+ coenzyme research vial.

10 mg CJC-1295 (No DAC) and 10 mg Ipamorelin as two separate vials.

10 mg Tesamorelin and 10 mg Ipamorelin as two separate vials.

20 mg BPC-157 research vial — the larger aliquot UK HPLC catalogues list above 15 mg.

20 mg TB-500 (thymosin β4 fragment) research vial.

20 mg Semaglutide research vial. Laboratory reference — not Ozempic or Wegovy.

30 mg Semaglutide research vial. Not a licensed medicine.

40 mg Tirzepatide research vial. Not Mounjaro.

60 mg Tirzepatide research vial. Laboratory use only — not a licensed medicine.

30 mg MOTS-c research vial.

20 mg Tesamorelin (GHRH analogue) research vial. Not recombinant hGH.

20 mg KPV tripeptide research vial.

2 mg Cagrilintide research vial for smaller metabolic-pathway assays.